Related Experiment Videos
Maribavir (ViroPharma).
1Rigel Pharmaceuticals Inc, 180 Veterans Boulevard, South San Francisco, CA 94080, USA. hlu@rigel.com
Current Opinion in Investigational Drugs (London, England : 2000)
|December 17, 2004
Summary
Maribavir, a DNA synthesis inhibitor, is being developed to prevent and treat human cytomegalovirus infections in transplant recipients and HIV patients. A phase II trial began in July 2004 to evaluate its efficacy.
Area of Science:
- Virology
- Pharmacology
- Immunology
Background:
- Human cytomegalovirus (CMV) infections pose significant risks post-transplant.
- CMV complications include congenital transmission and severe illness in HIV patients.
- Existing treatments for CMV have limitations, necessitating new therapeutic approaches.
Purpose of the Study:
- To evaluate maribavir, a DNA synthesis inhibitor, for CMV prevention and treatment.
- To assess maribavir's potential in solid organ and hematopoietic stem cell transplant recipients.
- To investigate maribavir for congenital CMV transmission and in HIV-infected individuals.
Main Methods:
- Maribavir, licensed from GlaxoSmithKline, targets viral DNA synthesis.
- A Phase II clinical trial was initiated in July 2004.
- The study focuses on patient populations at high risk for CMV.
Main Results:
- Data on efficacy and safety are pending trial completion.
- Maribavir's mechanism of action is DNA synthesis inhibition.
- The trial aims to establish the therapeutic potential of maribavir.
Conclusions:
- Maribavir represents a promising therapeutic candidate for CMV infections.
- Further clinical evaluation is required to confirm its benefits.
- Successful development could significantly impact CMV management in vulnerable populations.